SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript

SI-BONE, Inc. (SIBN) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 24, 2026

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025Generates free cash flow in the Fourth Quarter 2025

GlobeNewsWire • Feb 23, 2026

Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

Si-Bone (SIBN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.

Zacks Investment Research • Feb 24, 2026

SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026

SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time.

GlobeNewsWire • Feb 17, 2026

Earnings Preview: Si-Bone (SIBN) Q4 Earnings Expected to Decline

Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 16, 2026

SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026

SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026.

GlobeNewsWire • Feb 2, 2026

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20% Fiscal Year 2025 worldwide revenue of $200.8 to $200.9 million, representing growth of ~20%

GlobeNewsWire • Jan 12, 2026

Should You Buy Si-Bone (SIBN) After Golden Cross?

After reaching an important support level, SiBone (SIBN) could be a good stock pick from a technical perspective. SIBN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Zacks Investment Research • Dec 5, 2025

SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025

SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, December 2, 2025, at 9:00 a.m. Pacific Time/ 12:00 p.m. Eastern Time.

GlobeNewsWire • Nov 18, 2025

Why SI-Bone Stock Was Crushing It Today

The medical device maker posted a satisfying beat-and-raise third quarter. During the period, it managed to narrow its net loss considerably.

The Motley Fool • Nov 11, 2025